Company intelligence / Profile preview

Fuzhou Tcelltech Biological Science and Technology Inc.

Ownership: Private
Development stage: Preclinical

Overview

Fuzhou Tcelltech is developing TX103, an autologous CAR-T cell therapy targeting B7-H3 for recurrent glioblastoma and high-grade gliomas. Early phase I clinical data presented at ASCO 2024 indicate the company is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy via intracavity/intraventricular administration in patients with recurrent GBM. The program has orphan drug designation for gliomas. No late-stage or commercial products are reported.

Therapeutic areas: Oncology
Modalities: Autologous CAR-T cell therapyGene therapiesImmunotherapies
Industry: Biotech

Drug pipeline

2 assets

B7-H3-targeted CAR-T cells

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Fuzhou Tcelltech Biological Science and Technology Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzhou Tcelltech Biological Science and Technology Inc..

Explore the full profile